Fulgent Genetics, Inc. (FLGT) stock
FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3046% below fair value
$24.66−0.19 (-0.76%)
Close on Nov 13, 2026Market cap $678.53MP/E –Yield –
Fulgent Genetics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Fulgent Genetics's EV/EBITDA was 3.8× on Apr 28, 2023, against 2.2× a year earlier. Over the last 4 years it ranged from 1.8× to 466.8×, with a median of 4.5×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Apr 28, 2023 | 3.8× | +1.9 |
| 2022 | Dec 30, 2022 | 1.8× | −1.9 |
| 2021 | Dec 31, 2021 | 3.7× | −14.2 |
| 2020 | Dec 31, 2020 | 17.8× | −28.1 |
| 2018 | Jan 31, 2018 | 46.0× | +1.1 |
| 2017 | Dec 29, 2017 | 44.9× | – |
See a number that looks wrong?